Next Generation Sequencing Market Size, Share & Trends Report

Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Targeted Sequencing & Resequencing), By Application (Oncology, Consumer Genomics), By Workflow, By End-use, And Segment Forecasts, 2021 - 2028

  • Published Date: Feb, 2021
  • Base Year for Estimate: 2020
  • Report ID: 978-1-68038-428-4
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2019
  • Number of Pages: 328

Report Overview

The global next generation sequencing market size was valued at USD 3.99 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 14.4% during the forecast period. Genome sequencing has been used to understand the spread of Covid-19 and has the potential to understand the impact of interventions and help guide treatments in the future. Covid-19 Genomics U.K. Consortium (COG-U.K.) was formed in March 2020 to analyze the coronavirus genome using Whole-Genome Sequencing (WGS). The consortium includes Wellcome Sanger Institute, the NHS, Public Health Agencies, and other academic institutions. These groups have collaborated to map the evolution and spread of the virus.

The U.K. NGS market size, by technology, 2017 - 2028 (USD Million)

The consortium is also focused on deciphering the transmission chain of the virus so that the spread can be stopped. Researchers at the University of Liverpool have also carried out sequencing analysis to analyze the unique genetic code from samples collected from different individuals.

Companies, such as ThermoFisher and Illumina, have also geared up to fight this pandemic with the help of sequencing. Illumina has already provided support and technology to conduct surveillance and track transmission. The company also aims to develop vaccines and therapies to ensure long-term global security and safety.

The global market is highly competitive. Major industry participants are collaborating with other companies to increase the use of their platforms for research as well as diagnostics use. For instance, in January 2021, Illumina announced multiple oncology partnerships with Merck, Myriad Genetics, Kura Oncology, and Bristol Myers Squibb to expand the utilization and reach of its TruSight Oncology pan-cancer assay

Application Insights

Oncology accounted for the largest revenue of over 28% in 2020. Next generation sequencing (NGS) coupled with bioinformatics tools holds potential in revolutionizing oncology research, diagnosis, and treatment. Advancements in NGS technology have led to improvements in cancer research indicating the dawn of the “molecular age” of cancer.

Leading companies, such as Illumina, are constantly working toward the development of NGS-based In Vitro Diagnostic (IVD) solutions for cancer diagnostics. For instance, in January 2021, Illumina collaborated with Myriad Genetics to develop a kit-based version of the latter’s myChoice companion diagnostic (CDx) test. This combines NGS technology with companion diagnostics to enhance the genomic profiles of tumor samples.

Several other market players also offer NGS solutions to support cancer research. For example, in January 2021, Merus N.V.; a clinical-stage immuno-oncology company; collaborated with National Cancer Center, Japan, and Erasmus University Medical Center, the Netherlands to evaluate its HER2/3-targeting bispecific antibody in solid tumors. Under this, Merus plans to support access to NGS testing for non-small cell lung, and pancreatic cancer.

Technology Insights

Targeted sequencing & resequencing dominated the NGS market in 2020 with a revenue share of over 73%. The technology offers economical alternatives for WGS and facilitates the in-depth investigation of genomic regions. RNA-based targeted sequencing is anticipated to witness lucrative growth in the coming years as a result of the rising demand for differential expression analysis.

Moreover, wide use of the Amplicon RNA-Seq technology for the targeted RNA sequencing for the diagnosis of schizophrenia and other disorders supports the growth. Availability of expression kits for apoptosis, cardiotoxicity, cell cycle, p450 & p53 pathway, cardiotoxicity, and other customized panels is anticipated to fuel segment growth in the coming years.

The WGS technology is anticipated to grow at a significant rate from 2021 to 2028. A rise in the use of WGS to combat Covid-19 is attributed to segment growth. Moreover, companies, such as Illumina, offer microbial WGS in the market as the first NGS method that can be used for infectious disease surveillance. Such technology can produce high data quality and rapid results. Furthermore, it can be used to identify, track, and respond to disease outbreaks in a region.

Workflow Insights

The sequencing segment accounted for the dominant revenue share of more than 54% in 2020 as sequencing is a critical step of the workflow. In addition, sequencing is a capital-intensive procedure and thus accounts for a higher revenue generation. With an expected increase in the implementation of WGS, the subsequent data generation from sequencing projects is expected to grow. Due to the large volumes of data generated after sequencing, analysis becomes a challenge. However, there are several tools available in the market that address these issues.

For instance, Illumina’s BaseSpace Suite helps analyze sequencing data and produces results in a short span. The company has also acquired DRAGEN Bio-IT Platform (DRAGEN), and Edico Genome to expand its data analysis offerings. Other companies, such as Genomatix and DNAnexus, offer cloud-based platforms for the analysis and management of large volumes of sequencing data.

End-use Insights

The academic research end-use segment held the largest share of more than 53% in 2020. The segment is projected to expand further at a steady CAGR from 2021 to 2028. This growth can be attributed to the application of NGS solutions in research projects that are carried out in universities and research centers. Furthermore, scholarships offered for Ph.D. projects in NGS are anticipated to drive demand for NGS products and services, thereby resulting in lucrative growth over the coming years.

Moreover, countries, such as Germany and the U.K., have several universities that offer NGS applications and molecular biology courses. For instance, the Wageningen University & Research, the Netherlands offers NGS facilities and technologies that can be used in various applications. The university uses instruments and platforms, such as Illumina HiSeq2500, MiSeq, and PacBio Sequel.

Global NGS market share, by end-use, 2020 (%)

Clinical research is expected to be the fastest-growing end-use segment from 2021 to 2028. This can be attributed to the rising penetration of NGS-based diagnostic tests that are CLIA-waived and under the process of clinical approval augmenting the demand for NGS solutions. In addition, commercially available clinical research solutions from Agilent, Illumina, Thermo Fisher Scientific, and other companies for target enrichment & detection are anticipated to provide this segment with high growth opportunities over the forecast period.

Regional Insights

North America dominated the global market with a revenue share of 49.77% in 2020. The presence of several clinical laboratories that use NGS to offer genetic testing services drives the regional market. In addition, the development and launch of novel products by key companies in North America boost the market growth. For instance, in August 2020, Quest Diagnostics launched Automated NGS Engine to power AncestryHealth, a consumer genetics offering by Ancestry. The platform offers genetic screening of risks for blood disorders, colon cancer, breast cancer, and heart diseases.

Asia Pacific is expected to be the fastest-growing regional market from 2021 to 2028. The presence of local companies, such as BGI Genomics, and NGS service providers including First BASE Laboratories Sdn Bhd, Macrogen Asia Pacific Pte Ltd., and others is expected to drive the market in the Asia Pacific. MedGenome Labs Ltd. offers NGS services to more than 5,500 clinicians and 1,600 hospitals across South Asia and India.

Key Companies & Market Share Insights

The industry is marked by high competition between the dominant players. Strategies adopted by these companies to enhance their market presence include the launch of novel platforms that are rapid, small-sized, and less expensive. For instance, in January 2021, Cerba Research launched two new; PCR-based and NGS-based; Covid-19 exploratory tools to support R&D for vaccine development against infectious diseases, including Covid-19. The NGS-based assay facilitates WGS of respiratory viruses and SARS-CoV-2.

In December 2020, Eurofins Genomics launched cost-effective, optimized, SARS-CoV-2 NGS services that offer sequencing of complete viral genomes. In May 2020, Roche launched the KAPA Target Enrichment portfolio for target enrichment during sequencing and KAPA HyperExome whole-exome research panel. Therefore, a rise in market competition coupled with the launch of novel products is expected to increase revenue generation in the market. Some of the key companies in the global next generation sequencing market include:

  • Illumina

  • QIAGEN

  • Thermo Fisher Scientific, Inc.

  • F. Hoffman-La Roche Ltd.

  • Oxford Nanopore Technologies

  • Genomatix GmbH

  • PierianDx

  • DNASTAR, Inc.

  • Eurofins GATC Biotech GmbH

  • Perkin Elmer, Inc.

  • BGI

  • Bio-Rad Laboratories, Inc.

Next Generation Sequencing Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 4.4 billion

Revenue forecast in 2028

USD 11.7 billion

Growth rate

CAGR of 14.4% from 2021 to 2028

Base year for estimation

2020

Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million/billion and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Technology, application, workflow, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; Germany; U.K. Italy; Spain; France; Japan; China; South Korea; Australia; India; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

Illumina; QIAGEN; Thermo Fisher Scientific, Inc.; F. Hoffman-La Roche Ltd.; Oxford Nanopore Technologies; Genomatix GmbH; PierianDx; DNASTAR, Inc.; Eurofins GATC Biotech GmbH; Perkin Elmer, Inc.; BGI; Bio-Rad Laboratories, Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For purpose of this study, Grand View Research has segmented the global next generation sequencing market report on the basis of technology, application, workflow, end-use, and region:

  • Technology Outlook (Revenue, USD Million, 2017 - 2028)

    • WGS

    • Whole Exome Sequencing

    • Targeted Sequencing & Resequencing

      • DNA-based

      • RNA-based

  • Application Outlook (Revenue, USD Million, 2017 - 2028)

    • Oncology

      • Diagnostics and Screening

        • Oncology Screening

          • Sporadic Cancer

          • Inherited Cancer

        • Companion Diagnostics

        • Other Diagnostics

      • Research Studies

    • Clinical Investigation

      • Infectious Diseases

      • Inherited Diseases

      • Idiopathic Diseases

      • Non-Communicable/Other Diseases

    • Reproductive Health

      • NIPT

        • Aneuploidy

        • Microdeletions

      • PGT

      • Newborn Genetic Screening

      • Single Gene Analysis

    • HLA Typing/Immune System Monitoring

    • Metagenomics, Epidemiology & Drug Development

    • Agrigenomics & Forensics

    • Consumer Genomics

  • Workflow Outlook (Revenue, USD Million, 2017 - 2028)

    • Pre-Sequencing

      • NGS Library Preparation Kits

      • Semi-automated Library Preparation

      • Automated Library Preparation

      • Clonal Amplification

    • Sequencing

    • NGS Data Analysis

      • NGS Primary Data Analysis

      • NGS Secondary Data Analysis

      • NGS Tertiary Data Analysis

  • End-use Outlook (Revenue, USD Million, 2017 - 2028)

    • Academic Research

    • Clinical Research

    • Hospitals & Clinics

    • Pharma & Biotech Entities

    • Other Users

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • Italy

      • Spain

      • France

    • Asia Pacific

      • Japan

      • China

      • South Korea

      • Australia

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.